Psychiatr. praxi 2019; 20(2e) [Klin Farmakol Farm. 2018;32(2):13-19]

Antiparkinsonian drugs, mental disorders in patients with Parkinson’s disease and drug-drug interactions

Michal Prokeš, Josef Suchopár
DrugAgency, a. s., Praha

Patients with Parkinson´s disease (PN), a common neurodegenerative disorder, suffer not only from movement disorder, but also from mental disorders including behavioral disorders and psychosis. These disorders are closely related to dopaminergic treatment of PN. Despite knowledge of the clinical features of these disorders, many patients may not be diagnosed in time. Another issue are drug-drug interactions, because patients with PN are treated for associated diseases usually by other physicians, who may not always be aware, that the antiparkinsonian or antipsychotic drugs interact with other commonly prescribed drugs. This article introduces the medical public to these problems and shows possible solutions.

Keywords: Parkinson’s disease, antiparkinsonian drugs, antipsychotics, drug interactions, quetiapine

Published: June 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. Antiparkinsonian drugs, mental disorders in patients with Parkinson’s disease and drug-drug interactions. Psychiatr. praxi. 2019;20(E-verze 2/19):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Masopust J, Vališ M. Psychofarmakoterapie psychických komplikací Parkinsonovy nemoci. Neurologie pro praxi 2004; 3: 155-159.
    2. Rektorová I. Současné možnosti diagnostiky a terapie Parkinsonovy nemoci. Neurológia pre prax 2009; 10 (Supl.2): 5-36.
    3. Kraus J. Antiparkinsonika. In: Remedia Compendium, 2009; čtvrté vydání, 207-220.
    4. Freijzer PL, Brenminkmeijer JH. Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation. Ned Tijdschr Geneeskd 2002; 146(12): 574-575.
    5. Norman C, Hesslinger B, Frauenknecht S, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30: 263-265. Go to original source... Go to PubMed...
    6. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry 1992; 53(8): 278-282.
    7. Edwards M. Adverse interacction of levodopa with tricyclic antidepressants. Practitioner 1982; 226: 1447-1449. Go to PubMed...
    8. Yu K-S, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69: 266-273. Go to original source... Go to PubMed...
    9. Cho-J-Y, Yu KS, Jang IJ, et al. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homotygotic EM genotype for CYP2C19. Br J Clin Pharmacol 2002; 53: 393-397. Go to original source... Go to PubMed...
    10. Ignjatovič AR, Miljkovic B, Todorovic D, et al. Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interactions study. Br J Clin Pharmacol 2009; 67(2): 199-208. Go to original source... Go to PubMed...
    11. Marsh L. Depression in Parkinson's disease: current knowledge. Curr Neurol Neurosci Rep 2013; 13(12): 409. doi: 10.1007/s11910-013-0409-5.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878671/pdf/nihms785730.pdf Go to original source... Go to PubMed...
    12. Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord 2015; 30(1): 90-102. Go to original source... Go to PubMed...
    13. Friedman JH. Behavioral Neurology 2013; 27(4): 469-477. Go to original source...
    14. Lucca JM, et al. An adverse drug interaction of haloperidol with levodopa. Indian J Psychol Med 2015; 37(2): 220-222. Go to original source... Go to PubMed...
    15. Fernandez HH, et al. Treatment of psychosis in Parkinson's Disease. Drug Saf 2003; 26: 643-659. Go to original source... Go to PubMed...
    16. Breier A, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52: 438-445. Go to original source... Go to PubMed...
    17. SPC: Tiapridal(R) (tiaprid), sanofi-aventis, 11/2016 http://www.sukl.sk/buxus/generate_page.php?page_id=386 & lie_id=44133
    18. Lees AJ, et al. J Neurol Neurosurg Psychiatry 1979; 42: 380-383. Go to original source... Go to PubMed...
    19. Miyasaka H, et al. A 78-year-old man with young onset parkinsonism and sudden death. No To Shinkei 1996; 48: 487-495. Go to PubMed...
    20. Anders M. Antipsychotika, in: Remedia Compendium, 2009; čtvrté vydání, 268-287.
    21. Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763. Go to original source... Go to PubMed...
    22. SPC: Leponex(R)(klozapin), BGP Products, 3/2017 (http://www.sukl.cz/modules/medication/search.php)
    23. Databáze lékových interakcí DrugAgency (dříve Infopharm), verze z října 2017.
    24. SPC: Kventiax(R)(quetiapin), Krka, 2/2017 (http://www.sukl.cz/modules/medication/search.php)
    25. Woosley RL, Heise CW, Romero KA (www.CredibleMeds.org), QTdrugs List, [18. 5. 2017], AZCERT, Inc., 1822 Innovation Park Dr., Oro Valley, AZ 85755, USA
    26. Prokeš M, Suchopár J. Prodloužení intervalu QT způsobené léky. Med. praxi 2014; 11 (1): 34-39.
    27. Dostál V. Pozdní komplikace Parkinsonovy choroby. Neurologie pro praxi 2013; 14(1): 28-32.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.